Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial
出版年份 2022 全文链接
标题
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial
作者
关键词
-
出版物
LANCET ONCOLOGY
Volume 23, Issue 11, Pages 1367-1377
出版商
Elsevier BV
发表日期
2022-09-30
DOI
10.1016/s1470-2045(22)00555-1
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Real-Time Detection of ESR1 Mutation in Blood by Droplet Digital PCR in the PADA-1 Trial: Feasibility and Cross-Validation with NGS
- (2022) Celine Callens et al. ANALYTICAL CHEMISTRY
- Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1
- (2022) Frédérique Berger et al. BMJ Open
- Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
- (2022) Francois-Clement Bidard et al. JOURNAL OF CLINICAL ONCOLOGY
- Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor–Positive, ERBB2-Negative Advanced Breast Cancer
- (2021) Antonio Llombart-Cussac et al. JAMA Oncology
- A single droplet digital PCR for ESR1 activating mutations detection in plasma
- (2020) Emmanuelle Jeannot et al. ONCOGENE
- ESR1 mutations and overall survival on fulvestrant versus exemestane in advanced hormone receptor positive breast cancer: A combined analysis of the phase III SoFEA and EFECT trials
- (2020) Nicholas C. Turner et al. CLINICAL CANCER RESEARCH
- Systemic Therapy for Estrogen Receptor–Positive, HER2-Negative Breast Cancer
- (2020) Harold J. Burstein NEW ENGLAND JOURNAL OF MEDICINE
- ESR1 mutations: a new biomarker in breast cancer
- (2019) Marcela Carausu et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations
- (2018) Rinath Jeselsohn et al. CANCER CELL
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
- (2017) Matthew P. Goetz et al. JOURNAL OF CLINICAL ONCOLOGY
- PlasmaESR1Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
- (2016) Charlotte Fribbens et al. JOURNAL OF CLINICAL ONCOLOGY
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- (2016) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
- (2013) Weiyi Toy et al. NATURE GENETICS
- Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
- (2010) Gordon JS Rustin et al. LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now